Boehringer’s $1 Billion Cancer Deal Will Pay to Put Envisagenics’ ALS Drug Into the Clinic
- Envisagenics said on 22 September 2026 that it has signed a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate selected tumour-specific targets from its SpliceCore platform for first-in-class therapies in solid tumours. It is eligible for more than $1bn, made up of an upfront payment, research funding, option fees, development, regulatory and commercial milestones, and royalties. No amounts were disclosed.
- Boehringer may apply the targets across antibody-drug conjugates, T-cell engagers and multispecific antibodies, and holds an option to license selected targets exclusively once the research programme ends. SpliceCore screens more than 14 million alternative RNA splicing events for tumour specificity, patient prevalence and suitability as a drug target.
- Chief executive Maria Pineda told Fierce Biotech the upfront and milestone payments will be used to take the company’s lead internal candidate into the clinic. That programme, ENV-375, is a preclinical antisense therapy for ALS, and Pineda described the money to BioXconomy as non-dilutive funding.
- SpliceCore has earlier partners in Bristol Myers Squibb, which signed an oncology research collaboration in 2022 and invested in the 2024 Series B, as well as Johnson & Johnson and Biogen. Boehringer’s oncology research head, Mark Petronczki, said alternative splicing gives access to a largely unexplored target space.
Deal read
Boehringer is buying options on cancer targets. Envisagenics plans to use the cash to become a company with a clinical-stage neuroscience asset.
- Most of the billion is an option on an option. Boehringer validates first and licenses later, so development milestones and royalties exist only for targets it chooses to take. Before any exercise, the committed money is an undisclosed upfront and research funding. It is the third discovery deal in six days to announce a headline without a denominator, after Orbis with Novo Nordisk at $1.4bn and BoomRay with Novartis at $900m.
- Oncology money, neuroscience destination. Partnership cash funding ENV-375 lets Envisagenics move an ALS programme towards the clinic without pricing a new round. It also ties part of that timeline to how quickly Boehringer’s research milestones arrive, which is a dependency investors in the next raise will price.
- The target pool is shared. BMS has run a SpliceCore oncology collaboration since 2022 and holds equity from the Series B, and Boehringer will now validate targets the platform had already identified. The release does not say how targets are divided between two oncology partners, and for competitors that allocation matters more than the headline.